Press Release Service
![Company](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CMN_Companies_to_Follow_2023_01_17_81d7a58868_1c503a0f51.png)
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Arsenal Bio
Main focus: Next-generation autologous T cell therapies
Company stage: Commercial
Diseases (gene editing): Cancer
Genome editing tool: CRISPR
Funding stage: Private
Location: South San Francisco, CA, USA
Website: https://www.arsenalbio.com/
Gene editing partnerships: Bristol Myers Squibb
![](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ArsenalBio_Logo_Black_Original_9864d5480a_e1fae1620d.jpg)
Arsenal Bio develops multiple proprietary technology platforms, CellFoundry™, PrimeR™ and CARchitecture™ which together with the CRISPR technology form the foundation for its next-generation therapies. While the company has yet to disclose its lead programmes, it has announced a collaboration with Bristol Myers Squibb (BMS) where the two companies will discover and develop T cell therapies for the treatment of solid tumours.